Stifel analyst maintained a Buy rating on National Oilwell Varco (NOV) on July 31, 2025.
1 report, 1 independent
Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Stifel analyst maintained a Buy rating on National Oilwell Varco (NOV) on July 31, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
National Oilwell Varco
oilfield services company
Nothing else this week.
-
Stifel
American investment bank
Related events
- Stifel maintained a Buy rating on Faron Pharmaceuticals Ltd. following a cash update.
- Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.
- Stifel upgraded Microsoft's stock rating to Buy from Hold.
- The Metals Company is seeking necessary permits for deep-sea operations, supported by a bullish analyst rating from Stifel.
- Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
Coverage
Newest first; wire copies grouped- Insider MonkeyStifel Holds the Line on NOV: Buy Rating Reaffirmed Despite Target Trim to $22 NOV Inc. (NYSE:NOV) is one of the stocks that look extremely cheap on paper. On July 16, 2025, Stifel analyst Stephen Ge